A retrospective study of GCSF administration in combination with platinum and immune checkpoint inhibitor therapy for extensive-stage small cell lung cancer

A retrospective study of GCSF administration in combination with platinum and immune checkpoint inhibitor therapy for extensive-stage small cell lung - A retrospective study of GCSF administration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056770

Enrollment

100

Registered

2025-01-21

Start date

2024-01-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive-stage small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Small cell lung cancer has been diagnosed pathologically or cytologically. 2. Cases in which immune checkpoint inhibitors have been used in combination with platinum drugs 3. Treatment progress can be collected on a medical record

Exclusion criteria

Exclusion criteria: Cases that the principal investigator judged to be inappropriate for enrollment

Design outcomes

Primary

Measure	Time frame
Incidence rate of FN	—

Secondary

Measure	Time frame
Overall survival, mortality rate due to infection, and use of GCSF preparations	—

Countries

Japan

Contacts

Public ContactHISASHI TANAKA

Hirosaki University Graduate School of Medicine Department of Respiratory Medicine

xyghx335@gmail.com0172395468

Outcome results